Roots Analysis
JANUARY 23, 2024
The peptide therapeutics market has undergone substantial evolution since the inception of insulin. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases.
The Pharma Data
AUGUST 20, 2020
DEVELOP A UNIFIED SCIENTIFIC VOICE. It has since expanded nationwide, threatening an important market for many Big Pharma players. . This week’s bidding in Shanghai was the third round under a procurement program launched in 2018 aimed at saving billions of dollars. Virtual Event. Source link.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
APRIL 13, 2021
New data from the Plant Based Foods Association (PBFA) and The Good Food Institute (GFI) shows that the retail sales of plant-based foods in the US grew by 27 percent in 2020, bringing its total market value to $7 billion. of the $7 billion market. Plant-Based Milk Sales. Plant-Based Meat Sales. billion in sales in 2020.
ACRP blog
NOVEMBER 8, 2023
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
ACRP blog
NOVEMBER 8, 2023
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
The Pharma Data
DECEMBER 31, 2020
where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. Reimer replaces Charlotte Russel and will be responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies.
The Pharma Data
DECEMBER 28, 2020
Prior to that, Dr. Zhang was an equity research analyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine.
Expert insights. Personalized for you.
40 
Let's personalize your content